Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Immuno-Efficacy of Multi-Epitope Chimeric Peptides Against Foot and Mouth Disease Virus: Potential Vaccine Candidates for Newly Emerged Serotype O and A

Version 1 : Received: 25 September 2021 / Approved: 28 September 2021 / Online: 28 September 2021 (10:56:20 CEST)

How to cite: AKTER, S.; Rahman, M.S.; Islam, M.R.; Akther, M.; Marjia, M.; Rahman, M.M.; Sultana, M.; Hossain, M.A. Immuno-Efficacy of Multi-Epitope Chimeric Peptides Against Foot and Mouth Disease Virus: Potential Vaccine Candidates for Newly Emerged Serotype O and A. Preprints 2021, 2021090463 (doi: 10.20944/preprints202109.0463.v1). AKTER, S.; Rahman, M.S.; Islam, M.R.; Akther, M.; Marjia, M.; Rahman, M.M.; Sultana, M.; Hossain, M.A. Immuno-Efficacy of Multi-Epitope Chimeric Peptides Against Foot and Mouth Disease Virus: Potential Vaccine Candidates for Newly Emerged Serotype O and A. Preprints 2021, 2021090463 (doi: 10.20944/preprints202109.0463.v1).

Abstract

Artificially designed, chimeric peptide-based recombinant vaccines are novel approaches to combat the phylogenetically diverse Foot and Mouth Disease (FMD) Virus (FMDV) strains. Among seven distinct serotypes, only serotype O and A are dominantly circulating in Bangladesh and neighbouring countries of Asia, where transboundary transmission, recurrent outbreaks and emergence of novel lineages FMDV are highly prevalent. The objective of this study was to develop multi-epitope recombinant peptides, procuring immunogenicity against circulating diverse subtypes of FMDV serotype O and A. Two chimeric peptides, named B1 (41.0 kDa) and B3 (39.3 kDa), have been designed to incorporate potential B-cell and T-cell epitopes selected from multiple FMDV strains, including previously reported and newly emerged sub-lineages. After expression, characterization and immunization of guineapigs with considerable antigen load of B1 and B3 followed by the serological assays revealed the significant protective immunogenicity, developed from the higher (100 µg) doses of both antigens, against most of the currently prevalent serotype O and A strains of FMDV. The efficient expression, antigenic stability, and multivalent immunogenic potency of the chimeric peptides strongly indicate their credibility as novel vaccine candidates for FMDV serotypes O and A circulating in Bangladesh and surrounding territories.

Keywords

Artificially designed; chimeric peptides; expression; FMDV; serotype O and A; vaccine candidate

Subject

LIFE SCIENCES, Virology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.